Utilization of a liver allograft from a hepatitis B surface antigen positive donor

Transplantation

Volumn 81, Issue 1, 2006, Pages 129-131

  Jin, Kee Ho ^a   Harrigan, P Richard ^b   Sherlock, Christopher H ^a,c   Steinbrecher, Urs P ^a   Erb, Siegfried R ^a   Mo, Theresa ^b   Chung, Stephen W ^a   Buczkowski, Andrezj K ^a   Intaraprasong, Pongphob ^a   Scudamore, Charles H ^a   Yoshida, Eric M ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia C Excel HIV/AIDS   (Canada)

^c British Columbia Transplant Society   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Adefovir; Hepatitis B virus; Lamivudine; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; CORTICOSTEROID; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATOVIR; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGETRON; PEGIFN; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DONOR; FEBRILE NEUTROPENIA; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LIVER CIRRHOSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA;

ADULT; CADAVER; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MUTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 31044444027     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000191946.49884.40     Document Type: Article

References (19)

1. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003; 7: 585.
2. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520.
3. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1350.
4. Arena JI, Varjas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003; 9: S48.
5. Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C- and hepatitis B core antibody positive grafts in orthotopic liver transplantation. Liver Transpl 2003; 9: 1053.
6. Dickson RC, Everhardt JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers positive for antibody to hepatitis B core antigen. The National Institute of Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668.
7. Dodson SF, Bonham CA, Geller DA, et al. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058.
8. Yao JDC, Beld MGHM, Sherlock CH, et al. Multicentre evaluation of the Versant hepatitis B DNA 3.0 assay. J Clin Micro 2004; 42: 800.
9. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714.
10. Gonzalez-Peralta RP, Andres JM, Tung FY, et al. Transplantation of a hepatitis B surface antigen-positive donor into a hepatitis B virus-negative recipient. Transplantation 1994; 54: 114.
11. Franchello A, Ghisetti V, Marzano A, et al. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role ol hepatitis delta coinfection. Liver Transpl 2005; 11: 922.
12. van Nunen AB, de Man RA, Heijtink RA, et al. Passive immunizationof chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral Hepat 2002; 9: 221.
13. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682.
14. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527.
15. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129.
16. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808.
17. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421.
18. Neff GW, Nery J, Lau DT, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004; 38: 1999.
19. Perrillo RP, Eason JD. The use of HBsAg-positive organ donors: far more than meet the eye? Liver Transpl 2005; 11: 875.